Le point sur l'utilisation d'estramustine dans le cancer de la prostate métastatique

S. Culine; L. Drouet; J. C. Eymard; K. Fizazi; G. Gravis; C. Hennequin; S. Oudard; V. Ravery; M. Zerbib

doi:10.1016/j.purol.2009.08.039

Le point sur l'utilisation d'estramustine dans le cancer de la prostate métastatique

Translated title of the contribution: Update on the use of estramustin in metastatic prostate cancer

S. Culine, L. Drouet, J. C. Eymard, K. Fizazi, G. Gravis, C. Hennequin, S. Oudard, V. Ravery, M. Zerbib

Research output: Contribution to journal › Short survey › peer-review

2 Citations (Scopus)

Abstract

Chemotherapy is indicated in metastatic castration-refractory prostate cancer. It aims at alleviating symptoms and increasing survival, without impairing quality of life. Docetaxel is considered as the reference treatment in this indication. However, several studies demonstrated the relevance of associating estramustin with docetaxel, due to the synergistic effect of the combination and the action of estramustin on resistance mechanisms. Moreover, the addition of estramustin to chemotherapy demonstrated a survival benefit for patients. Thrombotic events are frequent in patients with advanced prostate cancer and estramustine is known to increase the risk. Optimization of treatment requires a thorough assessment of the individual risk in each patient as well as the prescription of an anti-thrombotic prophylaxis, which should be currently based on low molecular weight heparin.

Translated title of the contribution	Update on the use of estramustin in metastatic prostate cancer
Original language	French
Pages (from-to)	24-29
Number of pages	6
Journal	Progres en Urologie
Volume	20
Issue number	1
DOIs	https://doi.org/10.1016/j.purol.2009.08.039
Publication status	Published - 1 Jan 2010

Access to Document

10.1016/j.purol.2009.08.039

Cite this

@article{fbe215b96c35467d9932934fa05dcec7,

title = "Le point sur l'utilisation d'estramustine dans le cancer de la prostate m{\'e}tastatique",

abstract = "Chemotherapy is indicated in metastatic castration-refractory prostate cancer. It aims at alleviating symptoms and increasing survival, without impairing quality of life. Docetaxel is considered as the reference treatment in this indication. However, several studies demonstrated the relevance of associating estramustin with docetaxel, due to the synergistic effect of the combination and the action of estramustin on resistance mechanisms. Moreover, the addition of estramustin to chemotherapy demonstrated a survival benefit for patients. Thrombotic events are frequent in patients with advanced prostate cancer and estramustine is known to increase the risk. Optimization of treatment requires a thorough assessment of the individual risk in each patient as well as the prescription of an anti-thrombotic prophylaxis, which should be currently based on low molecular weight heparin.",

keywords = "Chemotherapy, Docetaxel, Estramustin, Metastatic prostate cancer",

author = "S. Culine and L. Drouet and Eymard, {J. C.} and K. Fizazi and G. Gravis and C. Hennequin and S. Oudard and V. Ravery and M. Zerbib",

year = "2010",

month = jan,

day = "1",

doi = "10.1016/j.purol.2009.08.039",

language = "Fran{\c c}ais",

volume = "20",

pages = "24--29",

journal = "Progres en Urologie",

issn = "1166-7087",

number = "1",

}

TY - JOUR

T1 - Le point sur l'utilisation d'estramustine dans le cancer de la prostate métastatique

AU - Culine, S.

AU - Drouet, L.

AU - Eymard, J. C.

AU - Fizazi, K.

AU - Gravis, G.

AU - Hennequin, C.

AU - Oudard, S.

AU - Ravery, V.

AU - Zerbib, M.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Chemotherapy is indicated in metastatic castration-refractory prostate cancer. It aims at alleviating symptoms and increasing survival, without impairing quality of life. Docetaxel is considered as the reference treatment in this indication. However, several studies demonstrated the relevance of associating estramustin with docetaxel, due to the synergistic effect of the combination and the action of estramustin on resistance mechanisms. Moreover, the addition of estramustin to chemotherapy demonstrated a survival benefit for patients. Thrombotic events are frequent in patients with advanced prostate cancer and estramustine is known to increase the risk. Optimization of treatment requires a thorough assessment of the individual risk in each patient as well as the prescription of an anti-thrombotic prophylaxis, which should be currently based on low molecular weight heparin.

AB - Chemotherapy is indicated in metastatic castration-refractory prostate cancer. It aims at alleviating symptoms and increasing survival, without impairing quality of life. Docetaxel is considered as the reference treatment in this indication. However, several studies demonstrated the relevance of associating estramustin with docetaxel, due to the synergistic effect of the combination and the action of estramustin on resistance mechanisms. Moreover, the addition of estramustin to chemotherapy demonstrated a survival benefit for patients. Thrombotic events are frequent in patients with advanced prostate cancer and estramustine is known to increase the risk. Optimization of treatment requires a thorough assessment of the individual risk in each patient as well as the prescription of an anti-thrombotic prophylaxis, which should be currently based on low molecular weight heparin.

KW - Chemotherapy

KW - Docetaxel

KW - Estramustin

KW - Metastatic prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=74149092648&partnerID=8YFLogxK

U2 - 10.1016/j.purol.2009.08.039

DO - 10.1016/j.purol.2009.08.039

M3 - Brève enquête

C2 - 20123524

AN - SCOPUS:74149092648

SN - 1166-7087

VL - 20

SP - 24

EP - 29

JO - Progres en Urologie

JF - Progres en Urologie

IS - 1

ER -

Le point sur l'utilisation d'estramustine dans le cancer de la prostate métastatique

Abstract

Access to Document

Other files and links

Cite this